Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Arrowhead Pharmaceuticals (ARWR)

Arrowhead Q3 revenue rises to $75.3 million; net loss widens to $194.3 million

Mixed Impact 3 of 5 earnings Written later

Arrowhead Pharmaceuticals reported fiscal third-quarter 2026 results for the period ended June 30, 2026. Revenue rose to $75.3 million from $27.8 million a year earlier, but the net loss attributable to Arrowhead widened to $194.3 million, or $1.36 per diluted share, from $175.2 million, or $1.26 per share, as research and development and selling, general and administrative expenses increased.

Key points

  • Revenue was $75.3 million for the quarter, compared with $27.8 million in the prior-year quarter.
  • Net loss attributable to Arrowhead was $194.3 million, or $1.36 per diluted share, versus $175.2 million, or $1.26 per share, a year earlier.
  • Research and development expense was $198.2 million, up from $162.4 million, and SG&A expense was $47.1 million, up from $30.9 million.
  • Total cash resources were $1.57 billion at June 30, 2026, compared with $781.5 million at September 30, 2025.

The filing

CompanyArrowhead Pharmaceuticals (ARWR)
Form8-K, current report
Filed with the SECAug 4, 2026, 4:03 PM ET
Accession number0000879407-26-000058

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.